Decreased Prostaglandin Production

DrugDrug NameDrug Indication
DB00586DiclofenacFor the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
DB00945Acetylsalicylic acid**Pain, fever, and inflammation** Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label]. The _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label]. **Other indications** ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label]. Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label]. For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label]. For the prevention of thromboembolism after hip replacement surgery [FDA label]. For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label]. Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label]. **Important note regarding use of the extended-release formulation [F4405]** In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].
DrugDrug NameTargetType
DB00586DiclofenacProstaglandin G/H synthase 1target
DB00586DiclofenacProstaglandin G/H synthase 2target
DB00586DiclofenacTransthyretincarrier
DB00586DiclofenacCytochrome P450 2C9enzyme
DB00586DiclofenacCytochrome P450 2C19enzyme
DB00586DiclofenacCytochrome P450 1A2enzyme
DB00586DiclofenacCytochrome P450 2C8enzyme
DB00586DiclofenacUDP-glucuronosyltransferase 1-1enzyme
DB00586DiclofenacSerum albumincarrier
DB00586DiclofenacMultidrug resistance-associated protein 4transporter
DB00586DiclofenacMultidrug resistance protein 1transporter
DB00586DiclofenacMultidrug resistance-associated protein 1transporter
DB00586DiclofenacSolute carrier family 22 member 6transporter
DB00586DiclofenacSolute carrier family 22 member 8transporter
DB00586DiclofenacSolute carrier organic anion transporter family member 1C1transporter
DB00586DiclofenacSolute carrier family 22 member 11transporter
DB00586DiclofenacUDP-glucuronosyltransferase 2B7enzyme
DB00586DiclofenacProstaglandin G/H synthase 1enzyme
DB00586DiclofenacCytochrome P450 3A4enzyme
DB00586DiclofenacCytochrome P450 1A1enzyme
DB00586DiclofenacCytochrome P450 2B6enzyme
DB00586DiclofenacCytochrome P450 2C18enzyme
DB00586DiclofenacCytochrome P450 2E1enzyme
DB00586DiclofenacArachidonate 5-lipoxygenasetarget
DB00586DiclofenacSodium channel protein type 4 subunit alphatarget
DB00586DiclofenacAcid-sensing ion channel 1target
DB00586DiclofenacPotassium voltage-gated channel subfamily KQT member 2target
DB00586DiclofenacPotassium voltage-gated channel subfamily KQT member 3target
DB00586DiclofenacPhospholipase A2, membrane associatedtarget
DB00586DiclofenacSolute carrier organic anion transporter family member 1B1transporter
DB00586DiclofenacBile salt export pumptransporter
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidNuclear factor kappa b beta subunittarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidTumor necrosis factor-inducible gene 6 proteintarget
DB00945Acetylsalicylic acidCaspase-1target
DB00945Acetylsalicylic acidCaspase-3target
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidExtracellular signal-regulated kinase (ERK)target
DB00945Acetylsalicylic acidG1/S-specific cyclin-D1target
DB00945Acetylsalicylic acidMyc proto-oncogene proteintarget
DB00945Acetylsalicylic acidProliferating cell nuclear antigentarget
DB00945Acetylsalicylic acidCyclin Atarget
DB00945Acetylsalicylic acidUDP-glucuronosyltransferase 1-6enzyme
DB00945Acetylsalicylic acidArylamine N-acetyltransferase 2enzyme
DB00945Acetylsalicylic acidSolute carrier family 22 member 8transporter